Back

Keratin 5 marks cancer-propagating cells sustained by an osteopontin-producing niche in high-grade serous ovarian carcinoma

Bidarimath, M.; Ralston, C. Q.; Bidarimath, N.; Rose, I. M.; Colina, D.; Schmoeckel, E.; Godwin, A. K.; Mayr, D.; Ellenson, L. H.; Flesken-Nikitin, A.; Nikitin, A. Y.

2026-01-30 cancer biology
10.64898/2026.01.28.702332 bioRxiv
Show abstract

High-grade serous carcinoma (HGSC) is the most common and aggressive form of ovarian cancer. Advanced HGSCs exhibit pronounced cellular heterogeneity, including a subset of cancer-propagating cells (CPCs, also known as cancer stem cells) that are highly tumorigenic and display stem cell-associated properties such as self-renewal and chemoresistance. In contrast, a substantial fraction of HGSC cells is non-tumorigenic. The role of these non-cancer-propagating cells (non-CPCs) and their relationship to CPCs remain poorly understood. Here, we demonstrate that neoplastic cells expressing the intermediate filament protein keratin 5 (KRT5) represent bona fide CPCs. KRT5 cells form cancer organoids over successive passages, are tumorigenic in serial dilution xenograft assays, and are resistant to the antineoplastic agents, doxorubicin and cisplatin. Single-cell lineage-tracing experiments show that KRT5 CPCs give rise to KRT5- cells. KRT5 and KRT5- populations exhibit distinct gene expression profiles, with KRT5- cells characterized by expression of SPP1, which encodes the secreted factor osteopontin (OPN). Treatment with OPN enhances HGSC organoid growth and chemoresistance, whereas SPP1 knockdown reverses these effects. Together, these findings support a model in which HGSC contains two hierarchically related cell populations: KRT5, OPN-responsive CPCs and KRT5-, non-tumorigenic cells that form a niche producing OPN. Targeting pathways that sustain both stem-like tumor cells and their supportive niche may enable reduced dosing of highly toxic chemotherapeutic agents while enhancing therapeutic efficacy in HGSC.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Cell Reports
1338 papers in training set
Top 0.1%
22.3%
2
Cancer Research
116 papers in training set
Top 0.1%
14.2%
3
JCI Insight
241 papers in training set
Top 0.5%
6.3%
4
Cancers
200 papers in training set
Top 2%
3.5%
5
Clinical Cancer Research
58 papers in training set
Top 0.5%
3.5%
6
Cell Reports Medicine
140 papers in training set
Top 2%
3.2%
50% of probability mass above
7
npj Precision Oncology
48 papers in training set
Top 0.2%
3.0%
8
Molecular Cancer Research
42 papers in training set
Top 0.1%
2.8%
9
Oncogene
76 papers in training set
Top 0.8%
2.1%
10
Nature Communications
4913 papers in training set
Top 47%
2.1%
11
eLife
5422 papers in training set
Top 36%
2.1%
12
Developmental Cell
168 papers in training set
Top 7%
1.9%
13
Scientific Reports
3102 papers in training set
Top 59%
1.7%
14
Gastroenterology
40 papers in training set
Top 1%
1.5%
15
Journal of Clinical Investigation
164 papers in training set
Top 4%
1.5%
16
British Journal of Cancer
42 papers in training set
Top 1%
1.3%
17
International Journal of Cancer
42 papers in training set
Top 0.9%
1.2%
18
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 8%
0.9%
19
Cell Death & Disease
126 papers in training set
Top 2%
0.9%
20
PLOS ONE
4510 papers in training set
Top 65%
0.9%
21
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 41%
0.9%
22
Neoplasia
22 papers in training set
Top 0.6%
0.8%
23
Molecular Cancer Therapeutics
33 papers in training set
Top 0.6%
0.8%
24
Cancer Discovery
61 papers in training set
Top 2%
0.7%
25
Cancer Research Communications
46 papers in training set
Top 1%
0.7%
26
Genes & Development
90 papers in training set
Top 1%
0.7%
27
Cancer Cell
38 papers in training set
Top 2%
0.6%
28
iScience
1063 papers in training set
Top 38%
0.6%
29
Communications Biology
886 papers in training set
Top 30%
0.6%